Pimasertib
- Generic Name
- Pimasertib
- Drug Type
- Small Molecule
- Chemical Formula
- C15H15FIN3O3
- CAS Number
- 1236699-92-5
- Unique Ingredient Identifier
- 6ON9RK82AL
- Background
Pimasertib is under investigation in clinical trial NCT01378377 (Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus).
A Study of Pimitespib in Combination with Imatinib in Patients with GIST (CHAPTER-GIST-101)
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 78
- Registration Number
- NCT05245968
- Locations
- 🇦🇺
Flinders Medical Center, Adelaide, Australia
🇦🇺Alfred Health, Melbourne, Australia
🇨🇳Beijing Cancer Hospital, Beijing, China
Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors
- Conditions
- MelanomaSolid TumorCRAF Gene AmplificationSpitzoid MelanomaPilocytic AstrocytomaPilocytic Astrocytoma, AdultNon Small Cell Lung CancerNon-Small Cell AdenocarcinomaColorectal CancerPancreatic Acinar Carcinoma
- Interventions
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Day One Biopharmaceuticals, Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT04985604
- Locations
- 🇺🇸
The Angeles Clinic, Los Angeles, California, United States
🇺🇸Hoag Health, Newport Beach, California, United States
🇺🇸University of Colorado Hospital, Aurora, Colorado, United States
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8Hormone Receptor Positive Breast AdenocarcinomaMetastatic Lung Non-Small Cell CarcinomaMetastatic Triple-Negative Breast CarcinomaStage IVA Lung Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Pathologic Stage IV Cutaneous Melanoma AJCC v8Stage IVB Lung Cancer AJCC v8Hematopoietic and Lymphoid Cell NeoplasmMetastatic Melanoma
- Interventions
- First Posted Date
- 2021-03-09
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT04789668
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Relative Bioavailability of Pimasertib in Cancer Patients
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 38
- Registration Number
- NCT01992874
- Locations
- 🇺🇸
Please Contact U.S. Medical Information Located in, Rockland, Massachusetts, United States
A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients
- First Posted Date
- 2013-11-15
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 26
- Registration Number
- NCT01985191
- Locations
- 🇳🇱
Investigational Site Number 528002, Utrecht, Netherlands
🇫🇷Investigational Site Number 250001, Villejuif Cedex, France
🇳🇱Investigational Site Number 528003, Rotterdam, Netherlands
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2013-09-06
- Last Posted Date
- 2018-12-12
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 65
- Registration Number
- NCT01936363
- Locations
- 🇪🇸
Research site, Valencia, Spain
Oral Bioavailability and Mass Balance Trial With Pimasertib
- First Posted Date
- 2012-10-24
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 6
- Registration Number
- NCT01713036
- Locations
- 🇭🇺
Research Site, Budapest, Hungary
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
- Conditions
- N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma
- Interventions
- First Posted Date
- 2012-09-26
- Last Posted Date
- 2018-01-05
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 194
- Registration Number
- NCT01693068
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
🇩🇪Research site, München, Germany
🇺🇸Please contact the US Medical Information in, Rockland, Massachusetts, United States
A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy
- Conditions
- Hepatocellular CarcinomaAdvanced Solid Tumors
- Interventions
- First Posted Date
- 2012-08-17
- Last Posted Date
- 2017-08-23
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 26
- Registration Number
- NCT01668017
- Locations
- 🇯🇵
Please contact, Merck Serono Co., Ltd for recruiting locations in, Japan
Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus
- First Posted Date
- 2011-06-22
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 33
- Registration Number
- NCT01378377
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸For Recruiting Locations in the US contact US Medical Information in, Rockland, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.